DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Waardenburg syndrome type 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleWaardenburg syndrome type 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for waardenburg syndrome type 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
paired box 3 (PAX3) — PAX3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3CMY · 1.95 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Waardenburg syndrome is a rare genetic disorder characterised by heterochromia, increased inter-canthal distance, distopia canthorum, pigmentary anomalies, and variable degrees of deafness, usually inherited in an autosomal dominant pattern. Two case reports from 2012 found no familial history in the patients discussed. A 1981 study of 27 subjects with a family history emphasised that the syndrome has a wide spectrum of phenotypic expression, and that accurate diagnosis depends on thorough family history and physical examination. Among 620 students in a deaf/blind school in Nigeria, four had Waardenburg syndrome (frequency 0.65%); all four had complete blue irides, white forelock, and sensorineural hearing loss ranging from severe to profound, with one subject stone deaf. Two of those four benefited from hearing aids.
Genetic analysis of seven patients in a 2016 study detected mutations in all seven. Four novel PAX3 gene mutations (c.72delG, c.185T>C, c.118C>T, c.128G>T) and one novel SOX10 mutation (c.422T>C) were reported; three non-synonymous SNPs were predicted as harmful. A 2006 study described two novel PAX3 mutations in families with Waardenburg syndrome type I, including a missense mutation (c.142 G > T) present in an affected individual and his clinically normal father, indicating incomplete penetrance. A 2017 study of one family found a MITF gene mutation (c.763C>T) that caused the mutant protein to localise aberrantly in both the nucleus and cytoplasm, unlike wild-type MITF which localised only in the nucleus.
No drug treatment is described in any of these abstracts. The only interventions mentioned are hearing aids for sensorineural deafness and patient counselling. What remains missing is any clinical trial of a pharmacological therapy, any attempt to reverse or prevent the hearing loss or pigmentary features, and any systematic effort to stratify patients by specific mutation type for targeted intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Indian journal of human genetics · 2012 · 13 citations · open access
Waardenburg syndrome: A rare genetic disorder, a report of two cases
AbstractWaardenburg syndrome (WS) is a rare genetic disorder. Patients have heterochromia or eyes with iris of different color, increased inter-canthal distance, distopia canthorum, pigmentation anomalies, and varying degree of deafness. It usually follows autosomal dominant pattern. In this report, two cases have been discussed but no familial history of WS has been found. Counseling of the patient is necessary and cases of irreversible deafness have been treated.
Waardenburg's Syndrome: Variations in Expressivity
AbstractTwenty-seven subjects with a family history of Waardenburg's syndrome were examined with respect to 18 specific characteristics of the syndrome, with particular emphasis in identifying the spectrum of the phenotypic expression of affected persons. Our results indicate that patients with the syndrome may have a variety of clinical signs, and an accurate diagnosis will therefore depend on a thorough and pertinent family history and physical examination.
[Mutation analysis of seven patients with Waardenburg syndrome].
AbstractOBJECTIVE: To perform genetic analysis for 7 patients with Waardenburg syndrome. METHODS: Potential mutation of MITF, PAX3, SOX10 and SNAI2 genes was screened by polymerase chain reaction and direct sequencing. Functions of non-synonymous polymorphisms were predicted with PolyPhen2 software. RESULTS: Seven mutations, including c.649-651delAGA (p.R217del), c.72delG (p.G24fs), c.185T>C (p.M62T), c.118C>T (p.Q40X), c.422T>C (p.L141P), c.640C>T (p.R214X) and c.28G>T(p.G43V), were detected in the patients. Among these, four mutations of the PAX3 gene (c.72delG, c.185T>C, c.118C>T and c.128G>T) and one SOX10 gene mutation (c.422T>C) were not reported previously. Three non-synonymous SNPs (c.185T>C, c.128G>T and c.422T>C) were predicted as harmful. CONCLUSION: Genetic mutations have been detected in all patients with Waardenburg syndrome.
Genetics and Molecular Biology · 2006 · 5 citations · open access
Waardenburg Syndrome: description of two novel mutations in the PAX3 gene, one of which incompletely penetrant
AbstractWe describe two different novel mutations in the PAX3 gene, detected in two families with cases of Waardenburg syndrome type I (WSI). The missense mutation detected in one family involved a single substitution in exon 2 (c.142 G > T) and was present both in the affected individual and in his clinically normal father. The mutation found in the second family consisted of a deletion of 13 bases, c.764-776del(TTACCCTGACATT), in exon 5.
Nigerian Journal of Medicine · 2010 · 3 citations · open access
Audiometric Findings in Waardenburg's Syndrome Amongst the Institutionalised Deaf / Blind in Kaduna-Nigeria
AbstractINTRODUCTION: Waardenburg's syndrome is a rare inherited disorder of congenital hearing loss and Pigmentary disturbances of the eyes, hair, skin and neural crest derivatives. METHODOLOGY: 620 students in a deaf/blind school were examined end four had Waardenburg's syndrome with a frequency of 0.65%. 2 males and 2 females with Waardenburg's syndrome and age ranges between 1019 years (mean 15.75 years) All 4 subjects had complete blue irides, white forelock and sensorineural hearing loss, and thus met the diagnostic criteria. They were then subjected to Audiometric assessment. RESULTS: Otoscopy was essentially normal but Audiometry revealed sensorineural hearing loss [SNHL] in all the subjects ranging from severe to profound with one subject being stone deaf. CONCLUSION: Waardenburg's syndrome is a rare disorder in our environment although it may be under reported. Two of the subjects benefited from amplification and were given hearing Aids. Provision of early amplification cannot be over emphasized.
[Study of gene mutation and pathogenetic mechanism for a family with Waardenburg syndrome].
AbstractOBJECTIVE: To explore the pathogenetic mechanism of a family affected with Waardenburg syndrome. METHODS: Clinical data of the family was collected. Potential mutation of the MITF, SOX10 and SNAI2 genes were screened. Plasmids for wild type (WT) and mutant MITF proteins were constructed to determine their exogenous expression and subcellular distribution by Western blotting and immunofluorescence assay, respectively. RESULTS: were confirmed. Both proteins were detected with the expected size. WT MITF protein only localized in the nucleus, whereas R255X protein showed aberrant localization in the nucleus as well as the cytoplasm. CONCLUSION: The c.763C>T mutation of the MITF gene probably underlies the disease in this family. The mutation can affect the subcellular distribution of MITF proteins in vitro, which may shed light on the molecular mechanism of Waardenburg syndrome caused by mutations of the MITF gene.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
